European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

AvenCell Europe GmbH, Dresden, Germany

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

AvenCell Europe GmbH
GEMoaB GmbH
GEMoaB Monoclonals GmbH

Register

Ut
District Court of Dresden HRB 30429
Lei
529900EWVGG2EHOEC574

Address

Tatzberg 47, 01307 Dresden, Germany

Corporate purpose

The production, development, application and marketing of chemicals and proteins for therapeutic purposes and all related activities; Manufacture, development, application and marketing of cell products for therapeutic purposes as well as all related activities.

Financials

Earnings Revenue Employees

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Legal Representatives

Marketing & Tech

Network

Loading network

Publications

5 Apr 2024
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022
7 Nov 2023
No longer Officer: Marika Geißler
22 Aug 2023
Officer (4)
28 Apr 2023
Annual report for the year ending 31/12/2021 · Balance sheet for 31/12/2021
1 Feb 2023 in Fts
EU funding (€260,539): 101072759 - Eternity - Fuel the Brain in Healtthy Aging and AGE-Related Diseases
31 Jan 2023 via Cellex Cell Professionals GmbH, also 22/03/2022
Shareholder: Cellex Cell Professionals GmbH
5 Oct 2022
Managing Director: Tapan Maniar · No longer Managing Director: Gerhard Ehninger
21 Sept 2022
Patent: Switchable Chimeric Antigen Receptors and Their USE
30 Mar 2022 as GEMoaB GmbH)
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020
13 Jan 2022 as GEMoaB GmbH
Wordmark: “Adira“
9 Dec 2021
Managing Director: Marc Cartellieri, Gerhard Ehninger · Name: AvenCell Europe GmbH · Corporate Purpose
6 Dec 2021 via CPT Cellex Patient Treatment GmbH
Merger: CPT Cellex Patient Treatment GmbH
6 Dec 2021 as GEMoaB GmbH
Merger: CPT Cellex Patient Treatment GmbH
30 Nov 2021
Original document: “Gesellschaftsvertrag / Satzung / Statut“
30 Nov 2021
Original document: “Unternehmensvertrag / Umwandlungsvertrag / sonstiger Vertrag“
8 Nov 2021
Patent: Targeting Modules Against IL13RA2 or HER2 for USE in Combination with a Chimeric Antigen Receptor
18 Oct 2021 as GEMoaB GmbH
No longer Managing Director: Michael Pehl
17 Sept 2021
Original document: “Liste der Gesellschafter“
16 Mar 2021
Patent: A Targeting Module Comprising PD-L1 and/or PD-L2 for USE in a Method for Stimulating a Chimeric Antigen Receptor Mediated Immune Response in a Mammal
4 Jan 2021 as GEMoaB GmbH
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018
10 Dec 2020 as GEMoaB GmbH
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019
23 Nov 2020 via CPT Cellex Patient Treatment GmbH
Control: CPT Cellex Patient Treatment GmbH
19 Oct 2020 as GEMoaB GmbH
No longer Managing Director: Volker Knöll · Capital: €250,000 · Share­holder agreement · Name: GEMoaB GmbH
16 Mar 2020
Patent: A Targeting Module Comprising PD-L1 and/or PD-L2 for USE in a Method for Stimulating a Chimeric Antigen Receptor Mediated Response in a Mammal
8 Jan 2020 as GEMoaB Monoclonals GmbH
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018
8 Jul 2019 as GEMoaB Monoclonals GmbH
Managing Director: Michael Pehl
12 Jun 2019 as GEMoaB GmbH
Patent: Reversed Universal Chimeric Antigen Receptor Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and USE of the Same for Treatment of …
2 Jan 2019 as GEMoaB Monoclonals GmbH
Patent: Genetic Modified Pluri- or Multipotent Stem Cells and Uses Thereof
Year 2018 in Epobase
4 European patent filings: Antibodies Against Prostate-Specific Stem Cell Antigen and USE Thereof …
23 Oct 2018 as GEMoaB Monoclonals GmbH
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017
15 May 2018 as GEMoaB Monoclonals GmbH
Managing Director: Gerhard Ehninger · No longer Managing Director: Elisabeth Ehninger
19 Feb 2018 as GEMoaB Monoclonals GmbH
Annual report for the year ending 31/12/2016 · Balance sheet for 31/12/2016
29 Nov 2017 as GEMoaB Monoclonals GmbH
Patent: Anti-la Antibodies and Their USE for Immunotargeting
25 Jan 2017 as GEMoaB Monoclonals GmbH
Annual report for the year ending 31/12/2015 · Balance sheet for 31/12/2015
8 Jun 2016
Patent: Genetically Modified, Pluri- or Multipotent Stem Cells and Uses Of These
1 Jun 2016 in Fk
Public funding (€1,730,643): TurbiCAR: UniCAR-based therapy CD123-positive leukemias - Sub-project preclinical development UNICAR-T and coordination clinical study
1 Jun 2016 in Fk
Public funding (€318,771): Compound TurbiCAR: UniCAR-based therapy CD123-positive leukemias - sub-projects preclinical evaluation of the investigational medicinal product
2 Mar 2016
Patent: Universal, Chimera Antigen Receptor Expressing Immune Cells Directed to Multiple Different Antigens, and Methods for Producing The Same and Using Them to Treat Cancer, Infections and …
26 Aug 2015
Patent: Universal Chimeric Antigen Receptor Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and USE of the Same for Treatment of Cancer …
5 May 2015 as GEMoaB Monoclonals GmbH
Patent: Genetic Modified Pluri- or Multipotent Stem Cells and Uses Thereof
27 Apr 2015 as GEMoaB Monoclonals GmbH
Officer: Marika Geißler · Address
13 Aug 2014 as GEMoaB Monoclonals GmbH
Patent: Anti-CD33 Antibodies and Their USE for Immunotargeting in the Treatment of CD33 Assosciated Pathologies
28 Jul 2014 as GEMoaB Monoclonals GmbH
Address
23 May 2014 as GEMoaB Monoclonals GmbH
Managing Director: Armin Ehninger, Volker Knöll
12 Dec 2013 as GEMoaB Monoclonals GmbH
Annual report for the year ending 31/12/2012 · Balance sheet for 31/12/2012
3 Jan 2013
Patent: Antibodies Against the Prostate-Specific Stem Cell Antigen and Its Use
3 Jan 2013 as GEMoaB Monoclonals GmbH
Patent: Antibodies against the prostate-specific stem cell antigen and its use
2 Jan 2013 as GEMoaB Monoclonals GmbH
Annual report for the year ending 31/12/2011 · Balance sheet for 31/12/2011
29 Jun 2012
Patent: Antibodies Directed Against the Prostate-Specific Stem Cell Antigen and ITS USE
9 Feb 2012
Patent: Anti-LA antibodies and their application for immunotargeting
9 Feb 2012
Patent: Anti-La Antibody and its application for immunotargeting
9 Feb 2012 as GEMoaB Monoclonals GmbH
Patent: Linker peptide and its use in fusion proteins
6 Oct 2011 as GEMoaB Monoclonals GmbH
Reg­is­tra­tion · Managing Director: Elisabeth Ehninger · Address · Capital: €25,000 · Share­holder agreement · Corporate Purpose
22 Sept 2011 as GEMoaB Monoclonals GmbH
Reg­is­tra­tion · Managing Director: Elisabeth Ehninger · Address · Capital: €25,000 · Legal form: GmbH · Name: GEMoaB Monoclonals GmbH · Corporate Purpose

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "AvenCell Europe GmbH, Dresden, Germany" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close